Novel Peptide Shows Promiseโ in overcoming Ovarian cancer โคDrug Resistance
[CITY, STATE] – researchers โฃhave identified a small peptide, Tฮฒ4-17, derived from thymosin ฮฒ4, that substantially enhances the effectiveness of cisplatin (DDP) – a common chemotherapy drug – in ovarian cancer cellsโค resistant โขto treatment. the study, utilizing ITRAQ technology for peptide โขselection, reveals thatโค Tฮฒ4-17 combats drugโ resistance by modulating the NF-ฮบB signaling pathway.
ovarian cancer remains a leading cause of gynecological cancerโ deaths, largely due to the growth โขof chemoresistance, whichโ drives recurrence and metastasis. This researchโข addresses this critical challenge by demonstrating that combining Tฮฒ4-17โข with โฃDDP effectively inhibits the proliferation โฃand migration of drug-resistant ovarian cancer cells, while simultaneously promoting apoptosisโฃ – โคprogrammed cell death.
Investigations usingโค qRT-PCR and Westernโฃ blot analysis confirmed elevated levels of NF-ฮบB expression in DDP-resistantโ ovarian cancer cells. โFurther experimentation, employing both NF-ฮบB โขinhibitorsโ andโค activators, showed thatโค Tฮฒ4-17 specifically downregulates the expression of the NF-ฮบB p65 protein. This downregulation correlatedโฃ with reduced cell proliferation and migration, as evidenced by Western blot,โ CCK8 assays, EDU fluorescence proliferation assays, โand cell scratch assays.
These findings indicate that Tฮฒ4-17 represents a potentialโค therapeutic strategy to โrestore chemo-sensitivity in ovarianโ cancer, offering a promising avenueโ for improvingโ treatment outcomes. โThe study โขconclusively demonstrates that Tฮฒ4-17 โฃenhances the sensitivity of โovarian cancerโ cells to DDP by downregulating NF-ฮบB expression.
Keywords: DDP; NF-ฮบB; Ovarian cancer; Peptides; Tฮฒ4-17.
